(2021) miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4. International immunopharmacology. p. 107355. ISSN 1878-1705 (Electronic) 1567-5769 (Linking)